Navigation Links
Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side
Date:9/3/2009

tances also inhibits tumor cell invasion. "This is an important protein that dogma said acts as an oncogene but which Dr. Toker demonstrated could also inhibit cancer spread, and thus may act as a suppressor for metastasis," Dr. Storz says.

Because Akt is an important negative-regulator of FOXO3a, the team looked at whether FOXO3a was actually the player with the Jekyll and Hyde split personality. They found that the transcription factor does indeed revert to its dangerous persona when a cancer cell becomes starved. "Our hypothesis is that if a cancer cell doesn't get the nutrients it needs, it turns on FOXO3a, which leads to the migration and invasion of tumor cells into areas with better growth conditions," Dr. Storz says. "This data fits neatly with Dr. Toker's findings about Akt, because Akt targets FOXO3a."


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related biology news :

1. General tumor marker test now offered by GenWay clinical laboratory
2. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
3. Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
4. $20 million NIH grant to transform clinical research at UIC
5. Systems biology recommended as a clinical approach to cancer
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
8. Versartis presents positive preclinical data on 2 product candidates at ENDO 09
9. Brain-computer interface, developed at Brown, begins new clinical trial
10. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
11. SNMs clinical trials network gains added support from industry leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... promoted as a clean-burning, renewable fuel that could help ... problems caused by ozone, compared with gasoline, especially in ... researchers. , Ozone production from both gasoline and ... 85 percent ethanol, is greater in warm sunny weather ... winter, because heat and sunlight contribute to ozone formation. ...
(Date:12/14/2009)... study to date of the proteins in a species ... clues to how similar regeneration could be induced in ... at Indiana University-Purdue University Indianapolis and colleagues investigated over ... a type of salamander that has the unique natural ... with the hope that this knowledge will contribute to ...
(Date:12/14/2009)... as a defining feature of humans. That,s until examples of ... and an array of other mammals. Now, a report in ... Cell Press publication, adds an octopus to the growing list ... a behavioral trick that the researchers call stilt walking. In ... shell "bowls," makes its eight arms rigid, and raises the ...
Breaking Biology News(10 mins):Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2New 21 The Groove Optic 28TM 29 for the Lux2940 28TM 29 3A A Breakthrough in Fractional Skin Resurfacing 6357 1New 21 The Groove Optic 28TM 29 for the Lux2940 28TM 29 3A A Breakthrough in Fractional Skin Resurfacing 6357 2New 21 The Groove Optic 28TM 29 for the Lux2940 28TM 29 3A A Breakthrough in Fractional Skin Resurfacing 6357 3Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 1Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 2Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 3Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 4Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 5Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 6Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 7Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 8Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 9Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 10Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 11Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 12Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 13Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results 6354 14Cancer patients and doctors report drug side effects differently 61571 1Cancer patients and doctors report drug side effects differently 61571 2
... a mud flat at the edge of the Cocheco River, ... Hampshire,s Contaminated Sediments Center are testing an innovative way to ... up the problem, or burying it under several feet of ... to cap and stabilize pollution in place. Over the next ...
... the human gene DRD4 is linked to better health ... settled cousins, according to new research by a team ... (UWM). , A study by UWM assistant professor Ben ... UNLV shows that a particular version of the gene ...
... human knees is even more common in dogs. Each ... cruciate ligament (CCL) deficiency, which is comparable to the ... method of treatment by many veterinary surgeons involves cutting ... these dogs. Now, a new minimally invasive technique with ...
Other Biology News:UNH researchers test sediment-scrubbing technology in NH river 2UNH researchers test sediment-scrubbing technology in NH river 3Did the gene for ADHD help our nomadic ancestors? 2Technique used in human ankle injuries modified to treat dogs' knees 2
(Date:12/11/2009)... Researchers have discovered a new explanation for differences in the ... of a certain gene, the more serious the handicap. The ... suspected that it is the amount of copies of the ... in the American Journal of Human Genetics , and ... Froyen connected to VIB, a life sciences research institute in ...
(Date:12/11/2009)... Corporation announced today the enrollment and dosing at the ... the first patient in the ACE ( AC ... 2 pivotal trial in patients with relapsed or refractory ... orally available, potent and highly selective small molecule that ... inhibitor. The ACE study is designed to be ...
(Date:12/11/2009)... Bio Innovations (MBI) today announces 2 new additions ... joined MBI as Senior Vice President of Commercial ... aspects of the company, including sales, marketing, and ... joined MBI as Vice President of Process Development, ... its broad pipeline of products to commercial manufacturing ...
(Date:12/11/2009)... CALGARY, Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... today announced the appointment of Dr. Alan Warrander ... Licensing and Business Development. ,, "Dr. Warrander will ... licensing strategy for REOLYSIN(R)," said Dr. Brad Thompson, ... agreement on the design of a Phase 3 ...
Breaking Biology Technology:Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
... Schizophrenia is a disease that strikes an average of ... disorder are not yet clear. But now, VIB researchers ... a disturbed cleavage of the Nrg-1 protein lies at ... understanding of this molecular process is a first step ...
... don,t clash of their own accord in our ... different. Two metal plates, placed almost infinitesimally close together, ... is known as the Casimir force, and it has ... heart of quantum physics: Seemingly empty space is not ...
... to Host Conference Call to Update Clinical Program ... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it ... clinical studies with,REOLYSIN(R), its proprietary formulation of the ... substantial momentum in the past year,culminating in the ...
Other Biology Technology:Incorrectly cleaved protein leads to schizophrenia 2Physicists tweak quantum force, reducing barrier to tiny devices 2Physicists tweak quantum force, reducing barrier to tiny devices 3Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R) 2Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R) 3
...
...
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
Biology Products: